PRKN and neoplasm: Similarly, treatment with the proteasome inhibitor, MG132 prevented Parkin degradation of K2 in cycloheximide block-and-release experiments (Fig. S6C) and preserved the speed of tumor cell movements and total distance traveled by individual cells, when compared to controls (Fig. S6, D and E).